BLA 761352 · Merus N.V.
Bizengri
Zenocutuzumab-Zbco · Solution
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Dec 4, 2024: To treat non-small cell lung cancer and pancreatic adenocarcinoma
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 4, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
10
4 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY Embryo-Fetal Toxicity: Exposure to BIZENGRI during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1 , 8.3) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Embryo-Fetal Toxicity: Exposure to BIZENGRI during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception [see Warnings and Precautions (5.4) , Use in Specific Populations (8.1 , 8.3) ].
What it is approved for
From the label in effect May 19, 2026.
BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) Adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy. ( 1.3 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.1 Advanced Unresectable or Metastatic NRG1 Fusion-Positive Non-Small Cell Lung Cancer BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Advanced Unresectable or Metastatic NRG1 Fusion-Positive Pancreatic Adenocarcinoma BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on...
Mechanism: Zenocutuzumab-zbco is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. Zenocutuzumab-zbco decreased cell proliferation and signaling through the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. In addition, zenocutuzumab-zbco mediates antibody-dependent cellular cytotoxicity (ADCC). Zenocutuzumab-zbco showed antitumor activity in mouse models of NRG1 fusion-positive lung and pancreatic cancers.
Therapeutic areas: Oncology · Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 2026 Supplement 10 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Dec 4, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- BIZENGRI · ZENOCUTUZUMAB-ZBCO 375MG/18.75ML · INJECTION, SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zenocutuzumab" as an intervention, any sponsor and status, largest first.
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Active, not recruiting
Partner Therapeutics, Inc.Industry
NCT02912949 · 250 participants (planned) · Start Jan 2015 · Primary completion Dec 31, 2026
Drug: zenocutuzumab (MCLA-128) · For: Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Fusion and 1 more
Sites: Phoenix, Arizona; Cerritos, California; Irvine, California · 64 sites in all
Merus B.V.Industry
NCT03321981 · 105 participants · Start Jan 15, 2018 · Primary completion Oct 26, 2022
Drug: Zenocutuzumab; Trastuzumab and 2 more · For: Breast Cancer Metastatic
Sites: Los Angeles, California; Kansas City, Kansas; Nashville, Tennessee · 25 sites in all
Partner Therapeutics, Inc.Industry
NCT05588609 · 13 participants · Start Nov 17, 2022 · Primary completion Jul 3, 2025
Drug: Afatinib Oral Tablet; Enzalutamide Pill and 2 more · For: NSCLC Harboring NRG1 Fusion; Metastatic Castration-resistant Prostate Cancer
Sites: Whittier, California; Lake Mary, Florida; Bethesda, Maryland · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2
- dysphonia2
- infusion related reaction2
- cardio-respiratory distress1
- diarrhoea1
- disease progression1
- drug intolerance1
- off label use1
- product label confusion1
- product strength confusion1
- product use issue1
- rash maculo-papular1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Schram AM, Goto K, Kim DW, et al. · N Engl J Med 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.
Cleary JM, Springfeld C, Arnold D, et al. · J Clin Oncol 2026 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Merus N.V.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.